ReproCELL Incorporated

Research ReproCELL Incorporated (6RC) on Bullrun: market cap EUR 68.57M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 68.57M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2026JPY 2.23B-JPY 591.69M-JPY 481.75M45.5%-6.25JPY 2.94Bn/aJPY 8.31B
FY2025JPY 2.98BJPY 103.25M-JPY 89.86M55.4%1.11JPY 2.82Bn/aJPY 8.98B
FY2024JPY 2.43B-JPY 31.42M-JPY 203.88M46.2%-0.37JPY 2.94Bn/aJPY 8.31B
FY2023JPY 2.95B-JPY 305.31M-JPY 301.57M38.6%-3.62JPY 1.91Bn/aJPY 7.58B
FY2022JPY 2.23B-JPY 575.09M-JPY 294.27M36.0%-7.57JPY 2.64BJPY 80.00MJPY 7.25B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-14EUR 68.57Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About ReproCELL Incorporated

ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is ReproCELL Incorporated's market cap?

ReproCELL Incorporated's market capitalization is EUR 68.57M.

What does ReproCELL Incorporated do?

ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, StemEdit gene edited iPSCs, mesenchymal stem cells (MSCs), and new immortalized cell lines and related reagents; and iPSC-derived exosomes.